on behalf of the Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators* Background-Peripheral artery disease (PAD) is common and imposes a high risk of major systemic and limb ischemic events. The REduction of Atherothrombosis for Continued Health (REACH) Registry is an international prospective registry of patients at risk of atherothrombosis caused by established arterial disease or the presence of Ն3 atherothrombotic risk factors. Methods and Results-We compared the 2-year rates of vascular-related hospitalizations and associated costs in US patients with established PAD across patient subgroups. Symptomatic PAD at enrollment was identified on the basis of current intermittent claudication with an ankle-brachial index (ABI) Ͻ0.90 or a history of lower-limb revascularization or amputation.
P eripheral artery disease (PAD) of the lower extremities has become increasingly recognized as a major contributor to the cardiovascular public health burden because it is associated with high rates of morbidity and impairment in quality of life and identifies a cohort of patients that is at increased risk of major cardiovascular ischemic events. [1] [2] [3] [4] [5] [6] Lower-extremity PAD is estimated to affect 12% to 15% of patients over age 65 years and between 8 and 10 million people in the United States, with the expectation that the prevalence will increase significantly as the population ages, becomes more obese, and as diabetes becomes more common. 3, 7 As a result, there has been an increased effort toward establishing greater awareness of the clinical burden and risks conferred by PAD. [7] [8] [9] Similarly, asso-ciated efforts are now directed toward establishing more effective diagnostic methods (including screening) and disease management guidelines aimed at increasing the use of therapies proven to reduce these risks. 10 In addition to the clinical burden on patients and their families, PAD is associated with a significant economic burden-in part related to the treatment of advanced disease aimed at alleviating symptoms as well as preventing and treating ischemic events. [11] [12] [13] Contemporary information regarding the impact of PAD on the risk of cardiovascular events has been provided by the REduction of Atherothrombosis for Continued Health (REACH) Registry, a large international prospective study of a stable outpatient population with either established symptomatic atherothrombosis (coronary artery disease [CAD] , cerebrovascular disease [CVD], or PAD) or Ն3 risk factors for atherothrombotic events. 14 Baseline data from REACH demonstrated a higher rate of polyvascular disease for patients with PAD than CAD or CVD and a greater degree of undertreatment of atherosclerosis risk factors in patients with PAD relative to those with CAD or CVD. 15 One-year follow-up data from REACH 6 and findings from other PAD registries 16 have revealed higher cardiovascular event rates for patients with PAD compared with patients with CAD or CVD, and more effective risk factor control in patients with PAD has been shown to be associated with a lower rate of cardiovascular events at 1 year. 17 An economic analysis of 1-year follow-up data from REACH patients enrolled from the United States demonstrated that symptomatic PAD was associated with greater vascular-related hospitalization rates and associated costs relative to CAD and CVD, largely because of costs associated with the high rate of peripheral artery revascularization procedures. 18 The current article incorporates the 2-year follow-up data and presents results from a more in-depth examination of rates of vascular events, PAD-related and other vascular interventions, and associated costs in patients with PAD enrolled from the United States to understand how healthcare resource use associated with systemic and limb-associated events and interventions varies according to symptomatic status and prior diagnostic/treatment history.
WHAT IS KNOWN
• Patients with peripheral arterial disease (PAD) constitute a high-risk population with higher rates of polyvascular disease, higher annual cardiovascular event and hospitalization rates, and greater associated costs relative to coronary artery disease or cerebrovascular disease.
WHAT THE STUDY ADDS
• This study provides an in-depth examination of long-term rates of vascular events, hospitalizations, and revascularization procedures in different PAD subgroups categorized according to symptomatic status and prior diagnostic/treatment history. • This study documents the existence of an iterative pattern of cost accrual related to high rates of recurrent rehospitalizations and repeat revascularization procedures in patients with symptomatic PAD. • The high rates of recurring rehospitalizations and revascularization procedures suggest that neither patients, physicians, nor healthcare systems should assume that an initial lower extremity PAD procedure serves as a permanent resolution of the underlying condition. • Cost estimates provided by this study are potential inputs into health economic models aimed at examining the long-term cost implications and cost-effectiveness of different treatment options, including secondary cardiovascular risk prevention strategies.
Methods
The design, 14 baseline characteristics, 15 
Definitions of PAD Categories
In concordance with the prospective analysis of PAD outcomes from the international REACH data base, 19 patients were assigned to 1 of the following 4 a priori-defined PAD subgroups using data collected at baseline: (1) asymptomatic if there was chart documentation of an ABI of Ͻ0.90 in the absence of lower-extremity ischemic symptoms;
(2) claudication if the chart documented this limb symptom along with an ABI of Ͻ0.90, in the absence of prior lower-limb revascularization or amputation; (3) prior lower-extremity revascularization if there was chart documentation of lower-extremity angioplasty, stenting, atherectomy, or a lower-extremity surgical bypass graft procedure in the absence of lower-limb amputation; or (4) amputation if the patient had a history of ischemic lower-limb amputation at any level. "Polyvascular disease" was defined as coexistent established (clinically recognized) arterial disease in 2 or 3 arterial territories (coronary, cerebral, and/or lower extremity). 19 
Healthcare Resource Use

Hospitalization Costs
Each reported hospitalization was assigned to 1 or more diagnosisrelated groups (DRGs), based on the primary reason for hospitalization and procedures (if any) performed. Hospital costs from the provider (ie, hospital) perspective were assigned using 2004 average costs, by DRG, obtained from the Medicare Provider Analysis and Review (MedPAR) database. 18, 20 These MedPAR-based hospital cost estimates are derived from individual hospital charges that were submitted to Medicare in 2004 and converted to costs using 2004 hospital level cost-to-charge ratios from the Medicare Cost Report. A weighted average of DRG-specific costs, with weights determined by the relative number of hospitalization records within MedPAR with each DRG, was used for hospitalizations for which more than 1 DRG may apply. Physician costs associated with hospitalizations were estimated as a percentage of hospital costs according to DRG and corresponding Medicare physician cost to hospital cost percentages. 21 This approach to the estimation of physician costs has been used in several recent health economic studies. 18, [22] [23] [24] 
Statistical Methods
One-year and cumulative 2-year costs associated with hospitalizations were estimated for the 82% and 64% of patients with available follow-up data, respectively. Rates of available follow-up data did not differ by PAD subgroup (range, 81% to 83%; 2 Pϭ0.63 at 1 year; range, 60% to 64%, Pϭ0.72 at 2 years). Baseline clinical and demographic characteristics did not differ between patients with and without complete follow-up data. Tests of differences between asymptomatic and symptomatic PAD subgroups and within symptomatic patients between subgroups defined according to prior diagnostic/treatment history-with respect to (1) baseline characteristics, (2) baseline medication use, (3) major cardiovascular event rates, and (4) the occurrence of Ն1 hospitalization during follow-up-were carried out using 2 or Fisher exact test for categorical variables and 1-way ANOVA for continuous variables. Generalized linear models (GLM) were used to evaluate the association between PAD subgroup and (1) number of medications per patient at baseline and (2) number of hospitalizations (total, and by type) per patient at 1 year (Poisson error distribution, log-link function). ANOVA was used to test the relationship between PAD subgroup and costs. Multivariable predictors of number of hospitalizations per patient and total hospitalization costs at 2 years were examined using GLM (Poisson and ␥ error distributions, respectively, log-link function).
Results
Baseline Characteristics
The distribution of patients according to PAD subgroup, and affected arterial beds, is shown in Figures 1 and 2 , respectively. Baseline characteristics for asymptomatic and symptomatic patient subgroups are presented in Table 1 for patients with available follow-up data through 1 year. The mean age was 71 years. Overall, 39% of these PAD patients were women. The prevalence of diabetes was 51%, ranging from 45% for patients with a history of revascularization to 73% for patients with a history of amputation. The prevalence of hypertension and hypercholesterolemia was high (88% and 80%, respectively) in the total PAD cohort and did not differ significantly by symptomatic status or between symptomatic subgroups. Twenty percent of patients were current smokers and 53% were prior smokers. The prevalence of prior TIA, stroke, stable angina, unstable angina, MI, percutaneous coronary intervention (PCI), CABG, and CHF varied by subgroup and was highest for patients with prior amputation. More than three fourths of patients with prior lower-limb revascularization underwent that revascularization Ͼ1 year before baseline, and Ͼ80% of patients with lower-limb amputation had that amputation Ͼ1 year before baseline.
Baseline Medication Use
Reported medication use at baseline is summarized in Table  2 . Overall, 81% of patients were receiving some form of antiplatelet therapy and 82% were receiving some form of lipid-lowering therapy (76% were receiving a statin); use of these medications was highest for patients with a prior revascularization (83% using an antiplatelet medication, 85% using lipid-lowering therapy, and 79% using a statin medication). Oral anticoagulant therapy was used by 18% of patients, with the highest reported use (22%) among patients with prior amputation. The overall use of claudication medications was 24%, with the highest (32%) among patients with a history of claudication but no prior revascularization or amputation. Use of multiple medications was high; the mean number of medications per patient was 5.8 (ranging from 5.5 for asymptomatic patients to 6.0 for patients with a history of amputation).
Two-Year Cardiovascular Events
Two-year rates of cardiovascular (CV) death (7.7% overall), the composite of CV death/MI/stroke (11.3% overall), and the composite of CV death/MI/stroke or CV hospitalization (28.0% overall) are presented in Table 3 . These rates did not differ significantly between asymptomatic and symptomatic subgroups. Within symptomatic subgroups, however, rates of all 3 cardiovascular end points at 2 years differed significantly, with patients with prior amputation having the highest rates and patients with a history of claudication but no prior revascularization or amputation having the lowest rates. 
Two-Year Vascular Hospitalization Rates and Associated Costs
Cumulative 2-year rates of hospitalizations, per 1000 patients, classified for the purpose of DRG assignment into those involving and not involving vascular procedures, are presented in Table 3 . It is important to note that some of the hospitalizations categorized as involving revascularization (eg, PCI/stenting) also involved a reported clinical event (eg, unstable angina or MI); the 19 categories of hospitalizations presented in Table 3 correspond to the characteristics of the hospitalization that determined the DRG assignment. Of those hospitalizations not involving any vascular procedures, overall rates of hospitalization were highest for CHF (106 per 1000 patients) and worsening of claudication (81 per 1000 patients), with significant variation between the patient subgroups for each. For hospitalizations involving vascular procedures, the highest rate (97 per 1000 patients, overall) was for peripheral angioplasty/stenting, with significant variation between subgroups. The rate of peripheral bypass grafting was also highest for patients with a history of peripheral revascularization (74 per 1000 patients). The rate of hospitalization for lower-limb amputation was highest for patients with a history of lower-limb amputation (90 per 1000 patients). The overall rates of hospitalization for coronary revascularization procedures were also high (51 and 24 per 1000 patients for PCI/stenting and CABG, respectively). The proportions of patients having at least 1 vascular-related hospitalization (including all those listed in Table 3 ) during the 2-year follow-up period were 23% and 31% for asymptomatic and symptomatic PAD patients, respectively (Pϭ0.07), and within the symptomatic subgroup were 25%, 32%, and 36% for patients with claudication, prior revascularization, and prior amputation, respectively (Pϭ0.0004). Mean 1-year and cumulative 2-year hospitalization costs per patient for the 4 PAD subgroups are shown in Figure 3 .
One-year costs are shown for the 2137 patients with available follow-up data through 1 year; results for the subset of 1677 patients with available data through 2 years differed very little ($3780, $4249, $6309, and $6162 for asymptomatic, claudication, revascularization, and amputation subgroups, respectively). Cumulative 2-year costs ranged from $7000 for patients with claudication and ABI Ͻ0.9 to $11 693 for patients with a history of lower-limb amputation (Pϭ0.007). Higher overall costs for patients with a history of lower-limb revascularization and for patients with a history of lower-limb amputation were due largely to the need for subsequent leg revascularization procedures and amputation procedures, respectively, during follow- up. Figure 4 shows that within each of the symptomatic PAD subgroups, 1-year and cumulative 2-year costs tend to be higher in patients for whom the PAD symptom or leg procedures defining the category (particularly prior revas-cularization) occurred during the year before enrollment in REACH. Table 4 presents results from an examination of the proportion of patients who underwent peripheral revascularization/amputation during the second year of follow-up according to baseline PAD subgroup and peripheral revascularization/amputation status during year 1. These results reveal that the rate of any peripheral intervention (revascularization or amputation) during the second year of follow-up is considerably higher for patients who underwent a peripheral intervention during the first year of follow-up, including for those who also had a history of revascularization or amputation before enrollment. Results from regression models examining the impact of baseline characteristics on 2-year hospitalization rates and associated costs are presented in Table 5 . After adjusting for other variables, a significant increase in hospitalization rates was associated with previous lower-limb revascularization, amputation, or claudication with ABI Ͻ0.90 within the year before baseline. As well, female sex and a history of diabetes, CHF, CAD, and CVD were also independently associated with a higher annual rate of vascular-related hospitalizations. Race was also a significant independent predictor of rehospitalization, with highest rates for Asian and lowest rates for patients categorized as "other." 25 The relative cost ratios presented in Table 5 , 4th column, correspond to the estimated multiplicative impact of the covariate on costs obtained from the GLM. Factors associated with significantly higher 2-year hospitalization costs were prior lower-limb revascularization (especially procedures within the year before baseline), claudication with ABI Ͻ0.9 within the year before baseline, history of diabetes, CHF, and female sex.
Discussion
A previous report from REACH estimated and compared vascular-related hospitalization costs in patients enrolled in the United States with symptomatic CAD, CVD, and PAD at enrollment and found costs to be higher for patients with symptomatic PAD, largely because of the high rate of peripheral revascularization procedures. Overall, approximately half of the hospitalization costs in patients with symptomatic PAD were due to PAD-specific treatment, whereas the other half were for the treatment of CAD or CVD-related atherothrombotic events or other cardiovascular reasons. Based on results from this prior study and 2004 US census data, total annual costs associated with vascular-related hospitalizations in patients with PAD were estimated to be in excess of $21 billion. 18 Results from the current analysis extend those previous results by examining 2-year hospitalization costs and demonstrate that these costs are high in patients with asymptomatic PAD as well and increase with increasing PAD clinical severity. This current report reveals especially high costs for patients with prior lower-limb revascularization, largely because of the need for repeat procedures.
A recent analysis of 2001 Medicare claims data examined PAD-related healthcare costs by identifying PAD cases on the basis of PAD-specific diagnosis and procedure codes and estimated total Medicare paid PAD-related inpatient care to be $3.4 billion in 2001. 11 Although this is lower than the roughly $10ϩ billion (in 2004 dollars) estimate of PAD-related hospitalization costs from REACH, the difference probably is explained by the considerably higher rates of CVD risk factors and prior cardiovascular events seen in the REACH US PAD cohort. The REACH cohort, compared with the Medicare beneficiary subset, included a broad population of PAD patients, and projection of costs was based on total US census data, as opposed to focusing 
Table 4. Proportion of Patients Who Had PAD Interventions (Revascularization or Amputation) During Second Year of Follow-Up According to Baseline PAD Subgroup and 1-Year PAD Intervention Status
PAD Intervention(s) During 1st
Year of Follow-Up only on Medicare-eligible patients. This is also reflected in the younger mean age of the REACH cohort-71 versus 76.5 years-and the later time frame for the REACH analysis. These results from REACH corroborate prior results regarding the high rates of peripheral revascularization and amputation that account for the majority of PAD-associated hospitalization costs. 11 The 2001 Medicare analysis reported a higher rate of peripheral bypass grafting than peripheral angioplasty, whereas the reverse was seen in REACH; this difference probably is due to the known temporal trend toward increasing use of endovascular procedures for revascularization of the lower limbs. 26 Alternatively, there may be selection bias with respect to the sites and patients enrolled in REACH relative to the overall US population, though site and patient selection in REACH was designed to be broadly representative of patients and practice patterns at the national level.
A study by Margolis et al 12 examined healthcare resources and costs attributable to the treatment of PAD using a large managed-care database covering from 1999 to 2003. Patients were identified on the basis of a medical claim for PAD (based on ICD-9 and CPT codes) or a pharmacy claim for cilostazol or pentoxyfylline; most (79%) of the PAD patients in their sample were considered newly diagnosed. Total average annualized costs of PAD-related care (including copayments, deductibles, coinsurances, drug costs, and PADassociated hospitalizations) were $5955 per PAD patient per year; costs associated with PAD-related procedures averaged No previous study has examined hospitalization rates and costs according to the PAD subgroups used in the current study. Although it might be assumed that PAD costs are only high in individuals who have severe claudication or critical limb ischemia, in whom lower extremity revascularization mandates use of expensive inpatient procedures, our data suggest that even patients with asymptomatic PAD create a significant health economic burden because of the high cardiovascular event rate and other cardiovascular-related hospitalizations. Moreover, our data demonstrate that when lower-extremity procedures are performed, substantial recurrent hospitalizations are common, with repeated revascularization procedures and associated costs. A critical implication is that neither patients, physicians, nor health systems should assume that a first admission for a lower extremity PAD procedure is a "cure" or that these legs are "fixed." In contrast, these data suggest that peripheral revascularization procedures tend to beget subsequent hospitalizations and procedures, with concomitant additional cost.
Although these data demonstrate the very high cost of PAD, we note that there are no data now available that clarify whether more effective use of preventive interventions (ie, more consistent use of risk reduction medications, access to supervised exercise programs, and smoking cessation strategies in this population) would reduce disease progression and costs associated with downstream vascular resource use 11 ; however, the potential seems likely. If progression of atherosclerosis in the lower extremities could be prevented or slowed so that proportionately fewer patients require peripheral revascularization procedures, the economic burden of these patients to the healthcare system might be considerably less. Prospective studies examining the effectiveness of different quality of care improvement initiatives in this area of secondary prevention seem warranted.
Limitations
This economic study is limited because outpatient care and chronic healthcare resource use, such as nursing home and rehabilitation after stroke or amputation, were not collected in the REACH Registry. In addition, we did not collect data on certain cardiac conditions (eg, arrhythmia management) or hospitalizations for noncardiovascular conditions. To the extent that these events may correlate with other cardiovascular events, it is likely that our cost estimates represent a systematic underestimate of the true economic burden in the US PAD patient population.
Also not included in this study are indirect costs associated with lost productivity on the part of the patient and other informal caregivers. Although the REACH Registry collected data relating to employment status and number of sick leave days owing to reported vascular outcomes occurring during follow-up, information relating to informal caregiver time was also not collected. Less than 20% of US REACH patients with PAD were working full-or part-time at baseline. Lost productivity costs among those patients were thus not included in the current analysis because they would account for only a small fraction of the indirect costs of atherothrombotic disease in this patient population. The limited healthcare resource use data collected in REACH required the application of average DRG-specific Medicare costs to reported hospitalizations and procedures, and the use of estimated physician cost percentages derived from 1992 Medicare data are also limitations of this cost study. The sample size for the asymptomatic patient subgroup is small, and results comparing that group with the symptomatic patient subgroup(s) must be interpreted with caution. Finally, the study is limited by incomplete follow-up data, especially for year 2, largely because of several enrolling sites within the United States declining further participation in the registry beyond the first year of follow-up. There was no evidence, however, that the sites that dropped out preferentially enrolled patients at higher or lower ischemic risk. One-year hospitalization costs based on all available data were similar to estimates based on data from patients who had complete follow-up data through 2 years; therefore there is no expectation that the overall findings are influenced significantly by the incomplete follow-up.
Conclusions
The economic burden associated with peripheral vascularrelated hospitalizations in patients with PAD is considerable. Stable patients with asymptomatic PAD have high annual costs, largely because of the high rate of cardiovascular events and hospitalizations, and costs escalate in the more symptomatic PAD categories because of the high rates of leg revascularization and other vascular-related procedures and hospitalizations. The high rates of recurring rehospitalizations and repeat revascularization procedures during the 2 years after peripheral revascularization suggest that neither patients, physicians, nor healthcare systems should assume that a first admission for a lower extremity PAD procedure serves as a permanent resolution of the underlying condition. Prospective studies of the effectiveness and cost-effectiveness of secondary prevention strategies aimed specifically at reducing PAD-related events seem warranted because effective interventions may curb the otherwise impending clinical and economic burden of PAD in the aging US population.
